Lercanidipin Heumann (Lercanidipine Hydrochloride)

• Lercanidipine is a calcium channel blocker used to manage elevated blood pressure within the antihypertensive drug class.
• Essential hypertension: reduces systolic and diastolic blood pressure, improving cardiovascular risk profile.
• Primary hypertension: provides sustained blood pressure control when lifestyle measures are insufficient.
• Secondary hypertension (e.g., renal or endocrine causes): assists in achieving target pressures alongside treatment of the underlying condition.

• Lercanidipine selectively inhibits L-type calcium channels in vascular smooth muscle, preventing calcium influx that is necessary for contraction. This inhibition leads to relaxation of arterial smooth muscle, vasodilation, and a consequent reduction in systemic vascular resistance, which lowers arterial blood pressure.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: warmth and redness, typically occurring shortly after dosing.
• Peripheral edema: swelling of the ankles or feet due to fluid accumulation.
• Dizziness or light‑headedness, especially when standing quickly.
• Tachycardia: an increase in heart rate that may accompany vasodilation.
• Fatigue: general feeling of tiredness without a clear cause.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue, or throat requiring immediate medical attention.
• Severe hypotension: marked drop in blood pressure leading to fainting or shock.
• Myocardial infarction: rare occurrence of heart attack symptoms.
• Hepatic injury: signs of liver dysfunction such as jaundice or elevated enzymes.
• Allergic reactions: rash, pruritus, or anaphylaxis requiring urgent care.

Before initiating therapy with Lercanidipine, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Blood pressure monitoring: check baseline and periodic readings to assess efficacy and avoid excessive hypotension.
• Cardiac assessment: review history of heart failure or ischemic disease before use.
• Concomitant antihypertensives: adjust doses of other blood‑pressure agents to prevent additive effects.
• Hepatic function: use caution in patients with moderate to severe liver impairment.
• Discontinuation: avoid abrupt cessation; taper if long‑term therapy is stopped.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of toxicity.
• Grapefruit juice: can markedly raise lercanidipine levels, leading to hypotension.
• Other calcium‑channel blockers: additive vasodilatory effects may cause severe hypotension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance blood‑pressure‑lowering effect, requiring dose adjustments.

• Beta‑blockers: combined use can lead to excessive heart‑rate reduction.
• ACE inhibitors or ARBs: monitor renal function and electrolytes for additive effects.
• NSAIDs: may blunt antihypertensive response, necessitating closer blood‑pressure monitoring.